| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/28/2023 | 1494.2% | HC Wainwright & Co. | → $22 | Reiterates | Buy → Buy |
| 08/02/2023 | 552.17% | Needham | $10 → $9 | Maintains | Buy |
| 06/26/2023 | 1494.2% | HC Wainwright & Co. | → $22 | Reiterates | Buy → Buy |
| 06/15/2023 | 189.86% | B of A Securities | $1.25 → $4 | Upgrades | Underperform → Buy |
| 06/01/2023 | 1494.2% | HC Wainwright & Co. | → $22 | Reiterates | → Buy |
| 05/09/2023 | 624.64% | Needham | $12 → $10 | Maintains | Buy |
| 04/18/2023 | 769.57% | Needham | → $12 | Reiterates | → Buy |
| 03/28/2023 | 769.57% | Needham | → $12 | Reiterates | → Buy |
| 03/20/2023 | 117.39% | Morgan Stanley | $9 → $3 | Maintains | Equal-Weight |
| 03/16/2023 | 8.7% | B of A Securities | $8 → $1.5 | Downgrades | Neutral → Underperform |
| 03/16/2023 | 769.57% | Needham | $16 → $12 | Maintains | Buy |
| 03/16/2023 | 1494.2% | HC Wainwright & Co. | → $22 | Reiterates | → Buy |
| 03/07/2023 | 407.25% | Credit Suisse | $6.5 → $7 | Upgrades | Underperform → Neutral |
| 03/06/2023 | 986.96% | JMP Securities | → $15 | Reiterates | → Market Outperform |
| 03/06/2023 | 1059.42% | Needham | $12 → $16 | Maintains | Buy |
| 03/06/2023 | 1494.2% | HC Wainwright & Co. | → $22 | Reiterates | → Buy |
| 02/27/2023 | 552.17% | JP Morgan | $8 → $9 | Maintains | Neutral |
| 02/27/2023 | 479.71% | B of A Securities | → $8 | Reinstates | → Neutral |
| 02/22/2023 | 769.57% | Needham | → $12 | Reiterates | → Buy |
| 02/03/2023 | 552.17% | Morgan Stanley | → $9 | Upgrades | Underweight → Equal-Weight |
| 11/02/2022 | 552.17% | Morgan Stanley | $7 → $9 | Maintains | Underweight |
| 08/03/2022 | 334.78% | Credit Suisse | $7 → $6 | Downgrades | Neutral → Underperform |
| 07/15/2022 | 407.25% | Morgan Stanley | $5 → $7 | Maintains | Underweight |
| 05/24/2022 | 117.39% | Goldman Sachs | $3.5 → $3 | Maintains | Sell |
| 05/05/2022 | — | JP Morgan | Upgrades | Underweight → Neutral | |
| 03/10/2022 | 1494.2% | HC Wainwright & Co. | → $22 | Initiates Coverage On | → Buy |
| 01/14/2022 | 334.78% | Credit Suisse | $8 → $6 | Maintains | Neutral |
| 12/09/2021 | 769.57% | Needham | $20 → $12 | Maintains | Buy |
| 12/06/2021 | 262.32% | Goldman Sachs | $8 → $5 | Maintains | Sell |
| 12/06/2021 | 479.71% | Credit Suisse | $11 → $8 | Maintains | Neutral |
| 10/19/2021 | 697.1% | Credit Suisse | $28 → $11 | Downgrades | Outperform → Neutral |
| 10/14/2021 | 697.1% | Morgan Stanley | → $11 | Downgrades | Equal-Weight → Underweight |
| 08/04/2021 | 1131.88% | Morgan Stanley | $22 → $17 | Maintains | Equal-Weight |
| 08/03/2021 | 8160.87% | Needham | $134 → $114 | Maintains | Strong Buy |
| 05/05/2021 | 2508.7% | Credit Suisse | $45 → $36 | Maintains | Outperform |
| 05/05/2021 | 1639.13% | Northland Capital Markets | $30 → $24 | Maintains | Market Perform |
| 05/05/2021 | 1494.2% | Morgan Stanley | $30 → $22 | Maintains | Equal-Weight |
| 05/05/2021 | 7943.48% | JMP Securities | $191 → $111 | Maintains | Market Outperform |
| 05/05/2021 | 1349.28% | Stifel | $37 → $20 | Downgrades | Buy → Hold |
| 03/11/2021 | 2073.91% | Morgan Stanley | → $30 | Initiates Coverage On | → Equal-Weight |
| 02/24/2021 | 9610.14% | Needham | $150 → $134 | Maintains | Strong Buy |
| 02/12/2021 | 2073.91% | Jefferies | $40 → $30 | Downgrades | Buy → Hold |
| 02/09/2021 | 1639.13% | Goldman Sachs | → $24 | Downgrades | Neutral → Sell |
| 01/15/2021 | 2436.23% | B of A Securities | → $35 | Downgrades | Buy → Neutral |
| 11/10/2020 | — | Credit Suisse | Upgrades | Neutral → Outperform | |
| 10/15/2020 | 3668.12% | B of A Securities | $55 → $52 | Maintains | Buy |
| 08/17/2020 | 3885.51% | B of A Securities | $60 → $55 | Maintains | Buy |
| 08/11/2020 | 3160.87% | Credit Suisse | $83 → $45 | Downgrades | Outperform → Neutral |
| 05/07/2020 | 4972.46% | Jefferies | $85 → $70 | Maintains | Buy |
| 04/16/2020 | 2943.48% | Northland Capital Markets | $60 → $42 | Maintains | Market Perform |
| 04/01/2020 | 3523.19% | B of A Securities | → $50 | Initiates Coverage On | → Buy |
| 03/17/2020 | — | Citigroup | Upgrades | Neutral → Buy | |
| 02/28/2020 | 3305.8% | JP Morgan | $46 → $47 | Maintains | Neutral |
| 02/24/2020 | 11349.28% | Needham | $144 → $158 | Maintains | Strong Buy |
| 02/24/2020 | — | Northland Capital Markets | Downgrades | Outperform → Market Perform | |
| 02/14/2020 | 5842.03% | Citigroup | $73 → $82 | Downgrades | Buy → Neutral |
| 09/18/2019 | 4972.46% | Stifel | $112 → $70 | Maintains | Buy |
| 09/16/2019 | 3160.87% | Goldman Sachs | $55 → $45 | Upgrades | Sell → Neutral |
| 05/29/2019 | 3523.19% | Goldman Sachs | → $50 | Downgrades | Neutral → Sell |
| 04/26/2019 | — | Goldman Sachs | Upgrades | Sell → Neutral | |
| 03/13/2019 | 3305.8% | JP Morgan | $38 → $47 | Upgrades | Underweight → Neutral |
| 12/13/2018 | 3160.87% | Goldman Sachs | → $45 | Initiates Coverage On | → Sell |
| 10/16/2018 | 5842.03% | BTIG | → $82 | Initiates Coverage On | → Buy |
What is the target price for Esperion Therapeutics (ESPR)?
The latest price target for Esperion Therapeutics (NASDAQ: ESPR) was reported by HC Wainwright & Co. on August 28, 2023. The analyst firm set a price target for $22.00 expecting ESPR to rise to within 12 months (a possible 1494.20% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Esperion Therapeutics (ESPR)?
The latest analyst rating for Esperion Therapeutics (NASDAQ: ESPR) was provided by HC Wainwright & Co., and Esperion Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Esperion Therapeutics (ESPR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Esperion Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Esperion Therapeutics was filed on August 28, 2023 so you should expect the next rating to be made available sometime around August 28, 2024.
Is the Analyst Rating Esperion Therapeutics (ESPR) correct?
While ratings are subjective and will change, the latest Esperion Therapeutics (ESPR) rating was a reiterated with a price target of $0.00 to $22.00. The current price Esperion Therapeutics (ESPR) is trading at is $1.38, which is within the analyst's predicted range.